Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04087733
Other study ID # 0003-08-2018
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date October 1, 2019
Est. completion date September 30, 2020

Study information

Verified date February 2021
Source University of Molise
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluation of the antimicrobial efficacy of a liposomal ozone-based solution (OZODROP®) , vs placebo in 200 patients undergoing cataract surgery by phacoemulsification . The clinical trial will last 3 days of treatment per patient. The conjunctival swab will be taken for each of the two eyes (in treatment and control) at T0 (before starting the treatment - 3 days before the cataract surgery) and at T3 (after 3 days of treatment - immediately before the cataract surgery). The last OZODROP instillation will take place 10 minutes before taking the sample.


Description:

The aim of the study is to assess the efficacy of a liposomal ozone-based solution (OZODROP®) in the preparation of the patient for cataract surgery, by evaluating the reduction of bacterial colonization of the conjunctiva. The study will be carried out at 18 surgical centers located throughout the national territory and will be conducted in accordance with the recommendations of Italian ethics committees. An informed consent will be provided to all study participants. 400 eyes of 200 patients undergoing cataract surgery by phacoemulsification will be included in the study. The clinical sample is divided into two groups, study group which will include treated and (GS) and control group (GC) eyes. The study group will be treated with OZODROP®, an isotonic ophthalmic solution composed of 0.5% ozonized oil in liposomes and hypromellose, while the GC will receive saline solution. At the time of recruitment, all eyes will undergo a complete examination, as usual, and the patient enrolled in the study will be shown how to proceed. The study includes 2 times, (T0) and (T3), equal for both groups in the study. 3 days before the cataract surgery (T0), two conjunctival swabs will be taken from the patients enrolled in the study, one in the eye to be operated and one in the control eye, who will be kept at a controlled temperature (+ 2 / + 7 ° C) and sent to the laboratory within 24 hours. Than, starting on the day of collection, the patients will instill the OZODROP® eye drops in the eye to be used (2 drops 4 times a day, 1 drop every 4 hours: 9:00 am, 1:00 pm, 5:00 pm: 00, h21: 00), while the untreated contralateral eye will serve as a control.Immediately before the cataract surgery (T3), the patients enrolled in the study will again receive two conjunctival swabs, one in the eye to be operated and one in the control eye. The last OZODROP® instillation will be carried out 10 minutes before the withdrawal. For the microbiological evaluation, the conjunctival swabs taken at T0 and T3 will be sent to the Microbiology laboratory. The reduction of conjunctival microbial flora, expressed as CFU, will be evaluated. Through the analysis of the parameters in the study, a significant reduction in the microbial flora of the conjunctiva is expected in patients undergoing treatment with OZODROP®.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date September 30, 2020
Est. primary completion date June 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age over 18 years 2. Patients eligible for cataract surgery 3. Willingness to participate in the study following the indications Exclusion Criteria: 1. Use of topical and / or systemic antibiotics and other topical antiseptics during the study 2. Presence of topical ocular therapies that cannot be suspended for the entire duration of the study 3. Ongoing ocular or systemic inflammatory or infectious processes 4. Hypersensitivity to the constituents of the preparation in study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
OZODROP
3 days before the cataract surgery (T0), two conjunctival swabs will be taken from the patients enrolled in the study, one in the eye to be operated and one in the control eye, who will be kept at a controlled temperature (+ 2 / + 7 ° C) and sent to the laboratory within 24 hours. Than, starting on the day of collection, the patients will instill the OZODROP® eye drops in the eye to be used (2 drops 4 times a day, 1 drop every 4 hours: 9:00 am, 1:00 pm, 5:00 pm: 00, h21: 00), while the contralateral eye will be treated with a saline solution and it will serve as a control. Immediately before the cataract surgery (T3), the patients enrolled in the study will again receive two conjunctival swabs, one in the eye to be operated and one in the control eye. The last OZODROP® instillation will be carried out 10 minutes before the withdrawal. For the microbiological evaluation, the conjunctival swabs taken at T0 and T3 will be sent to the Microbiology laboratory

Locations

Country Name City State
Italy University of Molise Campobasso

Sponsors (19)

Lead Sponsor Collaborator
University of Molise A.O.U. Città della Salute e della Scienza - Molinette Hospital, Azienda Ospedaliera Policlinico Mater Domini, Catanzaro, Azienda Ospedaliero-Universitaria Consorziale, Bari, Azienda Policlinico Umberto I, Roma, Casa di cura GEPOS, Telese, Centro Medico Oculistico ALSO, Saronno, Centro oftalmologico LASERVISTA, Caserta, Clinica Mediterranea, Napoli, Fondazione G.B. Bietti, IRCCS , Roma, Ospedale G. Panico, Tricase, Ospedale generale regionale F. Miulli, Acquaviva delle Fonti, Ospedale Policlinico Casilino, Roma, Ospedale San Carlo di Nancy, Roma, Ospedale Santa Croce-Carle Cuneo, Studio oculistico Franchini, Studio oculistico Laborante, U.C.O Ospedali Civico di Cristina Benfratelli, Università degli Studi del Molise, Clinica Oculistica

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reduction of conjunctival bacterial load assessed by CFU (Colony Forming Units) using Ozodrop in 200 patients before cataract surgery Reduction/eradication of conjunctival bacterial load in patients treated with ozodrop for three days before undergoing cataract surgery.
For the microbiological evaluation, the conjunctival swabs taken at T0 (before starting OZODROP instillation) and T3 (after instilling OZODROP 4 times/day for three days) will be sent to the Microbiology laboratory to be seeded, enriched and then isolated the different species under examination by suitable selective media. The different samples will be analyzed according to the routine methods used in microbiology. The untreated contralateral eye will serve as a control.
3 days